Merck & Co. Inc. closed 33.72% short of its 52-week high of $134.63, which the company achieved on June 25th.

Despite this potential, the stock has fallen by 25% in the past 12 months -- so is it a bargain buy right now? During the ...

Merck (NYSE:MRK) shares snaps six straight sessions of gains, as the stock closed 2.2% lower at $89.38 on Wednesday. The cancer drugmaker gained about 10% in the preceding six sessions.

Merck secures global rights to HRS-5346, an investigational Lp(a) inhibitor, in a deal with Hengrui Pharma worth up to $1.97 billion.

Image source: Getty Images ... which could be the catalysts Merck stock needs to sustain a rebound. What I like about Merck is its compelling value. Shares are trading at just 9 times the ...